NPs-mediated lncAFAP1-AS1
| 【Numbering】BKMC110001 | 【CAS】CAS | ||
| 【Item No.】BKMC110001-2 | 【specification】 | ||
|
|||
Name: NPs-mediated lncAFAP1-AS1
Composition: lncAFAP1-AS1 siRNA DSPE-PEG PDSA
Size: 300-500nm
Application: triple-negative breast cancer
Storage conditions: -4℃
Other instructions: sealed shelf life of half a year [main advantages] can synergistically enhance radiosensitivity and significantly improve the effect of radiotherapy in xenograft and metastatic tumor models.
Message
Composition: lncAFAP1-AS1 siRNA DSPE-PEG PDSA
Size: 300-500nm
Application: triple-negative breast cancer
Storage conditions: -4℃
Other instructions: sealed shelf life of half a year [main advantages] can synergistically enhance radiosensitivity and significantly improve the effect of radiotherapy in xenograft and metastatic tumor models.
Title:Nanoparticles (NPs)-Meditated LncRNA AFAP1-AS1 Silencing to Block Wnt/β-Catenin Signaling Pathway for Synergistic Reversal of Radioresistance and Effective Cancer Radiotherapy
Article link:https://cloud.tencent.com/developer/article/1785508
| Warm tips: Suzhou Beike nano products are only used for scientific research, not for human body,different batches of products have different specifications and performance |
Message
|
| Warm tips: Suzhou Beike nano products are only used for scientific research, not for human body,different batches of products have different specifications and performance.The website pictures are from the Internet. The pictures are for reference only. Please take the real object as the standard. In case of infringement, please contact us to delete them immediately. |
Previous： the end...
Next： 仿生巨噬細(xì)胞膜載CRISPR/Cas9
